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Abstract 
Objective: The purpose of this project is to educate providers and implement the use of the 
Screening Tool of Older Persons’ Prescriptions (STOPP) on patients 65 and older admitted as 
inpatients at Owensboro Health and reduce potentially inappropriate medications (PIMs).  
Background: Polypharmacy, the use of multiple medications or medications that are not medically 
necessary, is a persistent and growing problem for elderly patients in the United States. 
Polypharmacy has become synonymous with medications that are considered potentially 
inappropriate in individuals 65 or older. PIMs may be medications that, in the elderly, have 
deleterious effects, no indication, are used for treatment of the prescribing cascade, or medications 
that are continued beyond what is recommended or what is considered beneficial. Despite the 
extensive literature on the negative consequences of polypharmacy in the elderly population, the 
problem continues to grow. This problem continues because of the increased comorbid burden and 
prescribing cascade in the elderly. Determining effective interventions will be vital in ensuring the 
best outcomes for our aging population. 
Aim: Implement an educational intervention using STOPP. Assess the educational affects and rates 
of potentially inappropriate medications in those who received the STOPP intervention compared 
with those who received usual care. Outcomes assessed the differences in potentially inappropriate 
medications based on the categories within the STOPP criteria in a control group and an 
intervention group.  
Design: This was quasi-experimental, pre-post test design. Charts of 50 random patients meeting 
the inclusion criteria were assigned to a control group and charts of 50 random patients meeting 
inclusion criteria were assigned to an intervention group. Providers of patients in the intervention 
group received education on STOPP criteria. The number of potentially inappropriate medications 
from each category of STOPP criteria were measured at admission and at discharge in both groups. 
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Methods: The study was conducted at Owensboro Health a regional hospital in western Kentucky. 
The target sample included 100 random patients. Inclusion criteria were patients between the ages 
65 and 85 years old, admitted as inpatient, and on 5 or more medications. Exclusion criteria were 
patients younger than 65 or older than 85, receiving palliative or hospice care, and trauma or 
critical care patients. Chart audits were done using STOPP v.2 at admission and discharge in the 
control and intervention groups.  
Results: 46 patients in the control group and 42 patients in the intervention group met all the 
requirements for the study. A p-value of <0.05 was used for statistical significance in this study. 
The results revealed a statistically significant decrease in the total number of potentially 
inappropriate medications (PIMs; t= 3.296; p= 0.001). Categories within STOPP with statistically 
significant decreases in PIMs were indication (t= 2.518; p= 0.013), gastrointestinal drugs (t= 3.171; 
p= 0.002), and cardiovascular drugs (t= 2.343; p= 0.024). 
Conclusions: Results suggest that education on appropriate prescribing using STOPP as an 
intervention at the time of admission was successful in improving prescribing habits in elderly 
inpatients. This study suggests that using STOPP as an intervention was particularly successful in 
reducing PIMs in the specific categories: indication, gastrointestinal drugs, and cardiovascular 
drugs. Further research could incorporate strategies to expedite this process, including studies on 
implementation of STOPP criteria using computerized decision support software.  
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Introduction 
This is a report of the project “The Effects of STOPP Criteria on Potentially Inappropriate 
Prescribing in Elderly Inpatients.” The goal of this study was to improve prescribing habits in 
elderly inpatients to prevent the numerous negative consequences of polypharmacy and optimize 
outcomes in the aging population. The intervention used for this project was the Screening Tool of 
Older Persons’ Prescriptions (STOPP), the goal of which is to reduce polypharmacy in the elderly. 
The outcomes assessed the differences in potentially inappropriate medications based on the 
categories within the STOPP criteria in a control group and an intervention group. 
Background and Significance 
Multimorbidity, the co-occurrence of two or more chronic conditions, is a common 
occurrence in the elderly with more than 50% of older adults having three or more chronic 
conditions (AGS, 2012). The high prevalence of comorbidities makes the elderly, defined as 65 
years and older, more likely to be on multiple medications with complex drug regimens. 
Polypharmacy, the use of multiple medications or medications that are unnecessary, is a persistent 
and growing concern for elderly patients. In 2014, the National Center for Health Statistics (NCHS, 
2017) reported at least 42.4% of older adults were taking five or more prescription medications. As 
healthcare advances and treatments continue to be developed, it is likely that this number may 
continue to increase. 
An increase in the number of medications and complex drug regimens is associated with a 
significant decrease in medication adherence in older adults (Pasina et al., 2014). Other negative 
outcomes that may arise as a result of polypharmacy include increased costs (Kojima et al., 2012; 
Levy, 2012; Pergolizzi et al., 2014), increased fall rates (Levy, 2017), increased delirium and 
cognitive impairment (Levy, 2017), increased admission rates (Kojima et al., 2012) and adverse 
drug events (Kojima et al., 2012). Since it is common for elderly patients to have multiple medical 
conditions, these patients are at a higher risk for polypharmacy as well as the prescribing cascade, a 
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common situation in which providers prescribe new medications to treat the side effects of other 
medications (Greenleaf Brown, 2016). Elderly patients taking multiple medications are also at risk 
for consequences such as malnutrition, urinary incontinence, decreased functional ability and 
decreased ability to perform independent activities of daily living (Levy, 2017). 
Polypharmacy research has focused on understanding the trend of increasing healthcare 
costs and resource utilization, often a result of increased hospital admissions, emergency room 
visits, and adverse drug events (Kojima et al., 2012). One study of elderly adult residents in a long-
term care facility found the average cost of prescribed medications to be $874.27 per resident 
(Kojima et al., 2012). In a study on chronic pain treatment, drug interactions resulting from 
polypharmacy were associated with an average increase in cost of $609 a month (Pergolizzi et al., 
2014). 
Despite extensive research addressing the negative consequences of polypharmacy and 
potentially inappropriate medications, the problem continues to grow. Although existing research 
shows the negative effects of polypharmacy, this research has yet to transition into clinical practice 
changes. In fact, most elderly patients admitted to the hospital leave with even more medications 
(Gutiérrez-Valencia et al., 2017; Masnoon et al., 2017; Sganga et al., 2016) 
Targeted interventions can be used to reduce rates of polypharmacy and decrease healthcare 
costs (Kojima et al., 2012; Levy, 2017). Currently, there is no standardized program or method for 
reducing polypharmacy. However, the American Geriatric Society (AGS) proposes using protocols 
or algorithms such as the Beers criteria and the Screening Tool of Older Persons’ Prescriptions 
(STOPP; AGS, 2019; Levy, 2017). 
Theoretical and Conceptual Framework 
The Stetler model of evidence-based practice (Melnyk & Fineout-Overholt, 2015, pp. 278-
283) provided the necessary framework for the development and implementation of this study. 
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Phase I: the preparation stage involved defining the issue of polypharmacy and gathering sources. 
In phase II: validation, a rapid critical appraisal (Melnyk & Fineout-Overholt, 2015) was conducted 
on each source to determine validity. Phase III: comparative evaluation/decision making involved 
reviewing the literature and synthesizing common themes to evaluate the feasibility and fit in 
current practice, see appendix A. In phase IV, translation/application, the decision was made to 
conduct a study using STOPP for a dynamic evaluation within the planned setting. In phase V, 
evaluation, it was determined STOPP was successful in reducing PIMs which is discussed further 
in the results and discussion sections. 
Review of the Literature 
A search of the literature was conducted using CINAHL, PubMed, and ClinicalKey 
databases. Resulting articles included information on medication related falls in the elderly, costs 
of medication regimens, adverse drug events, Beers criteria, STOPP criteria, outpatient medication 
reviews, and inpatient medication reviews. Twelve articles met the inclusion criteria for this 
review. Four of these studies included randomized controlled trials. All of the studies 
acknowledged the negative consequences of polypharmacy in the elderly and the need for 
intervention.  
The American Geriatric Society calls for the use of tools such as Beers and STOPP criteria 
to reduce polypharmacy in this population (AGS; STOPP; Levy, 2017). STOPP was applied to 
older adults in multiple settings (Gallagher et al., 2011; Dalleur et al., 2014; Frankenthal et al., 
2014; O’Connor et al., 2016) including nursing homes, primary care and hospitals. The STOPP 
criteria were found to be more effective at reducing PIMs than other explicit criteria, including the 
Beers list (Gallagher et al., 2011; Dalleur et al., 2014; Frankenthal et al., 2014; O’Connor et al., 
2016). Reductions in PIMs using STOPP in an inpatient setting also led to sustained changes in 
PIMs after discharge (Gallagher et al., 2011; Dalleur et al., 2014; Frankenthal et al., 2014). 
Decreases in fall rates (Dalleur et al., 2014), drug-drug and drug-disease interactions (Gallagher et 
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al., 2011; O’Connor et al., 2016; Maldonado et al., 2014); increased adherence (Pasina et al., 2014), 
and lower monthly costs to the patient (Gallagher et al., 2011; Frankenthal et al., 2014; O’Connor 
et al., 2014) were achieved by identifying and discontinuing PIMs.  
Agency Description 
Setting 
The setting for this study was Owensboro Health, a regional hospital in Owensboro, 
Kentucky. The hospital serves twelve counties in western Kentucky and two counties in southern 
Indiana. Owensboro Health consists of 9 floors, over 40 departments, 477 inpatient beds and 30 
transitional care beds. 
Target Population  
The target population consisted of patients between the ages of 65 and 85 years, admitted to 
an inpatient unit. Patients were required to be on at least five medications. Individuals of any race 
and gender were included. Patients included had various admitting diagnoses, acute and/or chronic 
illnesses. Common admitting diagnoses include coronary artery disease, congestive heart failure, 
complications of diabetes mellitus, chronic obstructive pulmonary disease, gastrointestinal 
diseases, cancer, and orthopedic or general surgery procedures.  
Description of Stakeholders 
Key stakeholders include administrative positions at Owensboro Health. These 
administrative positions include the following executives: chief nursing officer, Joni Sims; chief 
quality and patient safety officer, Bill Bryant; chief operating officer, Debbie Bostic; and chief 
financial officer, John Hackbarth. Nurse managers, pharmacy managers, and house supervisors 
must be included because of their impact on implementation and compliance of clinical aspects of 
this project. Nurse practitioners, physicians, and physician assistants are key stakeholders because 
of the direct impact on clinical practice and prescribing habits. Pharmacists are key stakeholders 
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because of their role in reviewing medications and contacting providers. Nurses are included 
because of their role in determining admission medications, reviewing medications, providing input 
to providers on appropriateness of medications, and direct clinical care of the patients. Patients and 
caregivers are some of the most important stakeholders because of the direct effects that the 
outcomes will have on these individuals.  
Specific Aims 
The key objectives of this study were: 
A. To assess changes in the amount of potentially inappropriate medications in elderly 
inpatients after implementation of a STOPP intervention at time of admission.  
B. To assess changes within each category of STOPP criteria at discharge after 
implementation of a STOPP intervention.  
Methods 
Study Design 
The study used a quasi-experimental two sample, pre-post test design. A random sample of 
50 patients meeting the inclusion criteria was assigned to a control group. Data were collected at 
admission and discharge in the control group. A second random sample of 50 patients meeting the 
inclusion criteria was assigned to an intervention group. Data were then collected at admission in 
the intervention group. A provider notification of potentially inappropriate medications and 
education on STOPP criteria was then implemented in the intervention group. Data were then 
collected at discharge in the intervention group. Data collection for the control group and 
intervention group did not occur at the same time to avoid treatment effect in the control group.  
Demographic information of age, sex, and race was collected on all patients at the time of 
admission.  Data collected at the time of admission and again at discharge in both the control group 
10 
 
and intervention group included the number of potentially inappropriate medications from each 
category within STOPP.   
Sample 
This study used convenience sampling with random selection from all patients of the 
Admission Discharge Transfer (ADT) previous 24-hour inpatient admissions report between July 1, 
2019 to September 30, 2019 who met inclusion criteria. Inclusion criteria were patients: 1) between 
the ages of 65 and 85 years, 2) taking at least 5 medications at time of admission, and, 3) admitted 
as inpatient status. Exclusion criteria were patients: 1) younger than 65 years or older than 85 years, 
2) trauma or critical care patients, 3) palliative or hospice patients, 4) taking fewer than 5 
medications at the time of admission, and 5) outpatient or observation status. 
Procedures 
Measures 
The sample population was gathered from the ADT previous 24-hour inpatient admissions 
report. REDCap, an encrypted server using HIPAA compliant software, was used for data 
collection. Charts were audited through EPIC, the electronic medical record (EMR) used at this 
site. Medication information was collected from the prior to admission (PTA) medication list at 
admission and the after-visit summary (AVS) medication list at discharge. Screening Tool of Older 
Persons’ Prescriptions (STOPP) v.2 was used to audit the admission and discharge medication lists 
in both groups. STOPP contains 13 categories of potentially inappropriate medications, see 
appendix B. Dual IRB approval was received from Western IRB and University of Kentucky IRB, 
see appendices D and E. 
In the control group, patients received usual care; charts were audited at admission and at 
discharge to determine the total number of potentially inappropriate medications and the number of 
medications from each category of STOPP prescribed at that time. In the intervention group, charts 
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were audited at admission. In this group, education to providers included: 1) receiving the 
Screening Tool of Older Persons’ Prescriptions, and 2) notification of potentially inappropriate 
medications from individual charts with supporting STOPP criteria. Charts in the intervention 
group were then audited at discharge to determine post-intervention changes.  
Results 
Of the sample groups, 46 completed the study in the control group and 42 in the 
intervention group. Reasons for not completing the study included death, transfer to another facility 
or rehab unit, and transition to palliative/hospice care. The control and intervention groups were 
homogeneous in terms of age, race, and gender. The mean age was 75.43 in the control group and 
74.48 in the intervention group. There were slightly more males (n=25) compared to females 
(n=21) in the control group. The intervention group contained the same number of males (n=21) 
and females (n=21). Race in the control group was mostly Caucasian (n=40); other individuals 
were Black or African-American (n=4), Asian (n=1), and American Indian or Alaska native (n=1). 
In the intervention group, individuals were mostly Caucasian (n=38); other individuals were Black 
or African-American (n=3) and American Indian or Alaska native (n=1). 
 Overall, there was a statistically significant decrease in the total number of potentially 
inappropriate medications (p=0.001). Three categories showed a statistically significant reduction 
of PIMs: indication (p=0.013), gastrointestinal (p=0.02), and cardiovascular (p=0.024), see 
appendix F. Medications without indication were decreased by 13%, inappropriate gastrointestinal 
medications were reduced by 21.5%, and inappropriate cardiovascular medications were reduced 
by 11%. No statistically significant changes were found in the other ten categories. 
Discussion 
The aims of this study were to: Implement an educational intervention using STOPP, 
decrease the total amount of PIMs at discharge, and assess the rates of PIMs within each category 
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of STOPP in a control and intervention group. Results suggest education on appropriate prescribing 
and STOPP as an intervention is successful in reducing the total PIMs per patient at discharge. The 
largest impact at this facility was on PIMs from indication, gastrointestinal, and cardiovascular 
categories. These categories had some of the largest burden at Owensboro Health, see appendix C. 
By reducing the total number of PIMs, specifically from categories that have a significant impact 
on this facility, costs to the patient and pill burden are reduced in elderly patients at this hospital. 
The Stetler model was useful for gathering data and implementing an evidence-based intervention. 
The significant amount of criteria in STOPP prevented this study from considering a larger 
sample size due to time constraints. Many facilities may opt to use Beers list because of the more 
explicit nature of the criteria whereas the criteria in STOPP require having more information from 
patient labs, comorbidities, and prescription history. If STOPP criteria are used, computerized 
decision support software could make it more feasible for use in a hospital setting. The aims of this 
study were to identify and eliminate PIMs using STOPP. Overall, a decrease was achieved in the 
intervention group. However, this decrease was due to the decrease in three of the fifteen categories 
within STOPP. For this facility, STOPP may be useful in reducing polypharmacy in certain 
subgroups such as patients with cardiovascular and gastrointestinal diagnoses.  
Site-specific Facilitators and Barriers to Implementation 
The use of Epic, an electronic medical record, and the ability to quickly navigate patient 
charts expedited data collection. IT and security made it possible to access the necessary reports for 
gathering data. Pharmacy played a key role in conveying information to providers. Also, internal 
medicine providers seemed open to considering evidence-based changes suggested in this study. 
The Western Institutional Review Board (WIRB) is contracted out for research services because of 
the limited research done at this site; since WIRB conducts numerous services for various facilities, 
IRB approval was received quickly after submission.   
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Epic may have also been a barrier because the information included is only as accurate as 
the person entering the information. Some information may have not been accessible because of 
unintended omissions in charting. Another barrier was the limited resources for researchers at this 
site. There was no directory of research personnel or intranet information on conducting research 
what the expectations were for research conducted at this facility. The site of the study is not a 
research or teaching hospital; therefore, it took longer than expected to find the necessary channels 
for getting institutional approval, submitting to IRB, and receiving necessary IT/EPIC security 
clearances. 
Limitations 
This study had several limitations to note. The sample size of this study was small, 
consisting of 46 patients in the control group and 42 in the intervention group. The study consisted 
of the elderly at one facility. Due to the limited sample size, results from this study may not be 
generalizable to other hospitals or settings. During the timeframe of this study, the pharmacy at this 
facility also released the update of the Beers list and updates were posted throughout the hospital, 
which may have influenced the treatment effect in the intervention group. Also, the culture within 
this facility is not accustomed to participation in research or quality improvement projects and may 
have affected interest and participation.  
Implications for Future Nursing Research 
Despite the limitations of this study, there are implications for future research and use in 
practice. With the increasing number of elderly patients in society, health care providers must make 
strides to improve health outcomes for this population. Future studies might incorporate the use of 
the updated Beers list along with STOPP. It may also be beneficial to conduct a study comparing 
the new Beers list to STOPP.  One of the categories within STOPP is drugs that predictably 
increase the risk of falls in older adults. However, due to the classification of medications within 
this category, it is not possible to abruptly stop these medications without deleterious effects. For 
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example, benzodiazepines were included in this category and require weaning before 
discontinuation. Therefore, future studies could include a pathway for stopping these medications 
which could consist of a weaning protocol or transition onto a more appropriate medication. Future 
studies could also look at comorbid burden and identify clusters or patterns of burden load and 
include strategies for healthy aging.  
With the population aging at the current rate, organizations must identify ways to improve 
health in elderly Americans. Strategies for healthy aging need to be developed to approach health 
in the elderly in a standardized yet flexible manner. The John A. Hartford Foundation, a foundation 
dedicated to improving the health of America’s elderly, suggests the healthcare system focus on the 
4 “M”s: mentation, mobility, medications, and what matters. This study suggests STOPP may be 
useful to reduce polypharmacy in the elderly with a standardized approach to improve one of the 4 
“M”s: Medication. 
Conclusion 
 With the elderly population projected to double within the next 30 years, it is vital to 
determine interventions effective in improving the health of the older adult population (NCHS, 
2017; WHO, 2014). As the life span increases, the elderly population is projected to make up 1/4th 
of our society by 2060 (NCHS, 2017; WHO, 2014). Although healthcare has come a long way in 
increasing life span, it is important that these years are quality years. 
This study showed promising results for incorporating STOPP criteria for medication 
review in elderly patients admitted as inpatients. After this study was conducted, Owensboro 
Health is now discussing hiring a full-time pharmacist to review medications in elderly inpatients.  
Future studies are still needed to determine to what extent STOPP criteria could reduce potentially 
inappropriate medications in other categories. Future studies may incorporate larger sample sizes 
by conducting a study with a longer time frame. At this time, providers should consider using 
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STOPP in clinical practice along with other tools such as the Beers list. More research may be 
needed before STOPP is implemented as any type of standardized process or guideline throughout 
institutions. It is to all of our advantage to assist in identifying mechanisms and pathways that assist 
heath care providers in providing age-friendly healthcare systems and healthcare for all. 
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Appendix A: 
Synthesis of the Evidence 
 
Outcomes 1 2 3 4 5 6 7 8 9 10 11 12 
Medication adherence with 
intervention 
NE NE NE NE ↑ NE NE NE NE NE NE NE 
Decrease in PIMs 
↓ ↓ ↓ ↓ NE ↓ ↓ ↓ ↓ ↓ ↓ ↓ 
Cost-benefit improved 
↑ NE ↑ ↑ NE NE NE NE NE NE NE NE 
Fall rates 
↓ NE NE NE NE NE NE NE NE NE NE NE 
Risk of drug-drug & drug-
disease interaction 
NE NE ↓ ↓ NE ↓ NE NE NE NE NE NE 
Superiority* compared to 
other interventions 
NE NE NE ↑ NE NE ↑ NE ↑ ↑ NE NE 
PIMs restarted after 
discharge 
↓ ↓ ↓ NE NE NE NE NE NE NE NE NE 
1= Frankenthal, D., et al.; 2= Dalleur, O., et al.; 3= Gallagher, P., et al.; 4= O’Connor, M.N., 
et al.; 5= Pasina, L., et al.; 6= Maldonado, C., et al.; 7= Wickop, B., et al.; 8= Butool, I., et al.; 
9= Aung, T.H., et al.; 10= Patanwala, A., et al.; 11= Al-Hashar, A., et al.; 12= Vogelsmeier, A., 
et al. 
NE= Not evaluated 
*Superiority- Found more PIMs or meds associated with more negative consequences 
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Appendix B:  
Screening Tool of Older Persons’ Prescriptions (STOPP) version 2 
 
PLEASE NOTE: The very long list of references supporting each of the revised STOPP & START 
criteria is too large to include in the present paper. The full list of these references is available 
on the journal website http://ageing.oxfordjournals.org 
 
Screening Tool of Older Persons’ Prescriptions (STOPP) version 2. 
The following prescriptions are potentially inappropriate to use in patients aged 65 years and 
older. 
Section A: Indication of medication 
 
1. Any drug prescribed without an evidence-based clinical indication. 
2. Any drug prescribed beyond the recommended duration, where treatment duration is well 
defined. 
3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE 
inhibitors, anticoagulants (optimization of monotherapy within a single drug class should 
be observed prior to considering a new agent). 
 
Section B: Cardiovascular System 
 
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of 
benefit). 
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
4. Beta blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk 
of complete heart block, asystole). 
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias 
(higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). 
6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives 
available). 
7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or 
radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg 
elevation and /or compression hosiery usually more appropriate). 
8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), 
hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium 
> 2.65 mmol/l) or with a history of gout (hypokalaemia, hyponatraemia, hypercalcaemia and 
gout can be precipitated by thiazide diuretic). 
9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may 
exacerbate incontinence). 
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10. Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine, 
guanfacine), unless clear intolerance of, or lack of efficacy with, other classes of 
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antihypertensives (centrally-active antihypertensives are generally less well tolerated by 
older people than younger people). 
11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium- 
conserving drugs (e.g. ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum 
potassium (risk of dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be 
monitored regularly, i.e. at least every 6 months). 
13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in severe heart 
failure characterised by hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate 
therapy for angina (risk of cardiovascular collapse). 
 
Section C: Antiplatelet/Anticoagulant Drugs 
 
1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no 
evidence for increased efficacy). 
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent 
peptic ulcer ). 
3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor 
Xa inhibitors with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, 
bleeding diathesis, recent non-trivial spontaneous bleeding) (high risk of bleeding). 
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary 
stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has 
a high grade symptomatic carotid arterial stenosis (no evidence of added benefit over 
clopidogrel monotherapy). 
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa 
inhibitors in patients with chronic atrial fibrillation (no added benefit from aspirin) 
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa 
inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease (No 
added benefit from dual therapy). 
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger 
evidence and fewer side-effects). 
8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous 
thrombosis without continuing provoking risk factors (e.g. thrombophilia) for > 6 months, 
(no proven added benefit). 
9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary 
embolus without continuing provoking risk factors (e.g. thrombophilia) for > 12 months (no 
proven added benefit). 
10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
combination (risk of major gastrointestinal bleeding). 
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11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic 
ulcer disease). 
 
Section D: Central Nervous System and Psychotropic Drugs 
 
1. TriCyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism, or prior history of urinary retention (risk of worsening these 
conditions). 
2. Initiation of TriCyclic Antidepressants (TCAs) as first-line antidepressant treatment (higher 
risk of adverse drug reactions with TCAs than with SSRIs or SNRIs). 
3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects 
(chlorpromazine, clozapine, flupenthixol, fluphenzine, pipothiazine, promazine, 
zuclopenthixol) with a history of prostatism or previous urinary retention (high risk of urinary 
retention). 
4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant 
hyponatraemia i.e. serum Na+ < 130 mmol/l (risk of exacerbating or precipitating 
hyponatraemia). 
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged 
sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines 
should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a 
benzodiazepine withdrawal syndrome if stopped abruptly). 
6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy 
Body Disease (risk of severe extra-pyramidal symptoms). 
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic 
medications (risk of anticholinergic toxicity), 
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation 
of cognitive impairment). 
9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of 
dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments 
have failed (increased risk of stroke). 
10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of 
confusion, hypotension, extra-pyramidal side effects, falls). 
11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 
beats/min.), heart block or recurrent unexplained syncope or concurrent treatment with 
drugs that reduce heart rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of 
cardiac conduction failure, syncope and injury). 
12. Phenothiazines as first-line treatment, since safer and more efficacious alternatives exist 
(phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, with 
the exception of prochlorperazine for nausea/vomiting/vertigo, chlorpromazine for relief of 
persistent hiccoughs and levomepromazine as an anti-emetic in palliative care
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13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy) 
14. First-generation antihistamines (safer, less toxic antihistamines now widely available). 
 
Section E: Renal System. The following drugs are potentially inappropriate in older people with 
acute or chronic kidney disease with renal function below particular levels of eGFR (refer to 
summary of product characteristics datasheets and local formulary guidelines) 
1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of 
digoxin toxicity if plasma levels not measured). 
2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding). 
3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of 
bleeding). 
4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
Section F: Gastrointestinal System 
 
1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian 
symptoms). 
2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic 
dosage for > 8 weeks (dose reduction or earlier discontinuation indicated). 
3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, 
opioids, verapamil, aluminium antacids) in patients with chronic constipation where non- 
constipating alternatives are available (risk of exacerbation of constipation). 
4. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, 
ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced 
iron absorption above these doses). 
 
Section G: Respiratory System 
 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse 
effects due to narrow therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in 
moderate-severe COPD (unnecessary exposure to long-term side-effects of systemic 
corticosteroids and effective inhaled therapies are available). 
3. Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow angle 
glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary 
retention). 
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4. Non-selective beta-blocker (whether oral or topical for glaucoma) with a history of asthma 
requiring treatment (risk of increased bronchospasm). 
5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 
kPa (risk of exacerbation of respiratory failure). 
 
Section H: Musculoskeletal System 
 
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with 
history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or 
H2 antagonist (risk of peptic ulcer relapse). 
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart 
failure (risk of exacerbation of heart failure). 
3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where 
paracetamol has not been tried (simple analgesics preferable and usually as effective for 
pain relief). 
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of 
systemic corticosteroid side-effects). 
5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for 
osteoarthritis (risk of systemic corticosteroid side-effects). 
6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no 
contraindication to a xanthine-oxidase inhibitor (e.g. allopurinol, febuxostat) (xanthine- 
oxidase inhibitors are first choice prophylactic drugs in gout). 
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial 
infarction and stroke). 
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer 
disease). 
9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal 
disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper 
gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, 
oesophageal stricture). 
 
Section I: Urogenital System 
 
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased 
confusion, agitation) or narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or 
chronic prostatism (risk of urinary retention). 
2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic 
hypotension or micturition syncope (risk of precipitating recurrent syncope). 
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Section J. Endocrine System 
 
1. Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, 
glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia). 
2. Thiazolidenediones (e.g. rosiglitazone, pioglitazone) in patients with heart failure (risk of 
exacerbation of heart failure). 
3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of 
suppressing hypoglycaemic symptoms). 
4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of 
recurrence). 
5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial 
cancer). 
6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism 
(risk of androgen toxicity; no proven benefit outside of the hypogonadism indication). 
 
Section K: Drugs that predictably increase the risk of falls in older people 
 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-acting 
nitrates, ACE inhibitors, angiotensin I receptor blockers, ) with persistent postural 
hypotension i.e. recurrent drop in systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted daytime 
sedation, ataxia). 
 
Section L: Analgesic Drugs 
 
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, 
diamorphine, methadone, tramadol, pethidine, pentazocine) as first line therapy for mild 
pain (WHO analgesic ladder not observed). 
2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe 
constipation). 
3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence 
of severe pain). 
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Section N: Antimuscarinic/Anticholinergic Drug Burden 
 
Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. 
bladder antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation 
antihistamines) (risk of increased antimuscarinic/anticholinergic toxicity). 
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Appendix C: 
PIMs from Specific Categories of STOPP at Owensboro Health 
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Appendix D: 
Western IRB Approval  
May 8, 2019 
 
 
 
 
Jamie Leigh Edmiston Franks, BSN 
University of Kentucky 
3750 Ralph Avenue Apt 306 
Owensboro, Kentucky 42303 
 
Dear Ms. Franks: 
 
SUBJECT: IRB EXEMPTION— HIPAA FULL WAIVER OF AUTHORIZATION AND 
REGULATORY OPINION 
Investigator:  Jamie Leigh Edmiston Franks, BSN 
Protocol Title:  The Effects of STOPP Criteria on Potentially 
Inappropriate Prescribing in Elderly Inpatients 
 
On May 7, 2019, Western Institutional Review Board (WIRB) approved a request for 
a waiver of authorization for use and disclosure of protected health information (PHI) 
for the above-referenced research.  This review was conducted through expedited 
review.   
 
WAIVER OF HIPAA AUTHORIZATION 
 
WIRB determined that documentation received from you satisfies the three 
requirements for a waiver of authorization.  These requirements are: 
 
1. The use or disclosure of the PHI involves no more than minimal risk to the 
individuals, based on the following elements: 
 
a. An adequate plan to protect identifiers from improper use and disclosure; 
b. An adequate plan to destroy the identifiers at the earliest opportunity 
consistent with conduct of the research (unless there is a health or 
research justification for retaining the identifiers, or such retention is 
otherwise required by law); and 
c. Adequate written assurances that the PHI will not be reused or redisclosed 
to any other person or entity, except as required by law, for authorized 
oversight of the research project, or for other research for which the use or 
disclosure of PHI would be permitted by HIPAA. 
 
 
2. The research could not be practicably conducted without access to and use of 
the PHI; and 
 
3. The research could not practicably be conducted without the waiver. 
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The Board has determined that this waiver of authorization for the use and 
access of the protected health information as described in the above 
referenced protocol, and in the information provided in the submitted waiver of 
authorization form, is necessary for conduct of this research. 
 
 
REVIEW OF EXEMPTION REQUEST 
 
This is in response to your request for an exempt status determination for the above-
referenced protocol.  Western Institutional Review Board’s (WIRB’s) IRB Affairs 
Department reviewed the study under the Common Rule and applicable guidance. 
 
We believe the study is exempt under 45 CFR § 46.104(d)(4), because this is a 
retrospective chart review study where the information will not be recorded in a 
manner that the identity of the human subjects cannot readily be ascertained directly 
or through identifiers linked to the subjects.   
 
This exemption determination can apply to multiple sites, but it does not apply to any 
institution that has an institutional policy of requiring an entity other than WIRB (such 
as an internal IRB) to make exemption determinations.  WIRB cannot provide an 
exemption that overrides the jurisdiction of a local IRB or other institutional 
mechanism for determining exemptions.  You are responsible for ensuring that each 
site to which this exemption applies can and will accept WIRB’s exemption decision. 
 
Please note that any future changes to the project may affect its exempt status, and 
you may want to contact WIRB about the effect these changes may have on the 
exemption status before implementing them.  WIRB does not impose an expiration 
date on its IRB exemption determinations. 
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J.D., M.H.A., C.I.P., at 360-252-2852, or e-mail RegulatoryAffairs@wirb.com. 
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In implementing the research activities, you are responsible for complying with IRB decisions, conditions 
and requirements. The research procedures should be implemented as approved in the IRB protocol. It is 
the principal investigator's responsibility to ensure any changes planned for the research are submitted for 
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approval to eliminate apparent hazards to the subject(s) should be reported in writing immediately to the 
IRB. Furthermore, discontinuing a study or completion of a study is considered a change in the protocol’s 
status and therefore the IRB should be promptly notified in writing. 
 
For information describing investigator responsibilities after obtaining IRB approval, download and read the 
document "PI Guidance to Responsibilities, Qualifications, Records and Documentation of Human Subjects 
Research" available in the online Office of Research Integrity's IRB Survival Handbook. Additional 
information regarding IRB review, federal regulations, and institutional policies may be found through ORI's 
web site. If you have questions, need additional information, or would like a paper copy of the above 
mentioned document, contact the Office of Research Integrity at 859-257-9428. 
Section 1 Page 1 of 1 
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Appendix F:  
SPSS Output Data 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
DiffinMEDS contro1 46 .2174 .59304 .08744 
intervention 42 .6429 .61768 .09531 
Total number from all 
STOPP categories 
contro1 46 1.20 1.046 .154 
intervention 42 1.10 .726 .112 
Total number from all 
STOPP categories1 
contro1 46 .98 .882 .130 
intervention 42 .45 .593 .091 
 
 
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
DiffinMEDS Equal 
variances 
assumed 
2.804 .098 -
3.296 
86 .001 -.42547 .12910 -.68211 -.16882 
Equal 
variances 
not 
assumed 
  
-
3.289 
84.513 .001 -.42547 .12934 -.68266 -.16828 
Total number 
from all 
STOPP 
categories 
Equal 
variances 
assumed 
3.232 .076 .518 86 .606 .100 .194 -.285 .486 
Equal 
variances 
not 
assumed 
  
.527 80.442 .600 .100 .191 -.279 .480 
Total number 
from all 
Equal 
variances 
assumed 
.293 .590 3.252 86 .002 .526 .162 .204 .847 
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STOPP 
categories1 
Equal 
variances 
not 
assumed 
  
3.309 79.262 .001 .526 .159 .210 .842 
 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Antimuscarinic/ 
Anticholinergic Drug Burden 
contro1 46 .11 .434 .064 
intervention 42 .05 .309 .048 
Antimuscarinic/ 
Anticholinergic Drug 
Burden1 
contro1 46 .02 .147 .022 
intervention 42 .00 .000 .000 
 
 
 
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Antimuscarinic/ 
Anticholinergic 
Drug Burden 
Equal 
variances 
assumed 
2.272 .135 .755 86 .452 .061 .081 -.100 .222 
Equal 
variances 
not 
assumed 
  
.766 81.321 .446 .061 .080 -.098 .220 
Antimuscarinic/ 
Anticholinergic 
Drug Burden1 
Equal 
variances 
assumed 
3.816 .054 .955 86 .342 .022 .023 -.024 .067 
Equal 
variances 
not 
assumed 
  
1.000 45.000 .323 .022 .022 -.022 .066 
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Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Analgesic Drugs contro1 46 .02 .147 .022 
intervention 42 .05 .216 .033 
Analgesic Drugs1 contro1 46 .02 .147 .022 
intervention 42 .02 .154 .024 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Analgesic 
Drugs 
Equal 
variances 
assumed 
1.785 .185 -
.662 
86 .510 -.026 .039 -.104 .052 
Equal 
variances 
not 
assumed 
  
-
.651 
71.609 .517 -.026 .040 -.105 .053 
Analgesic 
Drugs1 
Equal 
variances 
assumed 
.017 .898 -
.064 
86 .949 -.002 .032 -.066 .062 
Equal 
variances 
not 
assumed 
  
-
.064 
84.407 .949 -.002 .032 -.066 .062 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Endocrine System contro1 46 .07 .250 .037 
intervention 42 .10 .297 .046 
Endocrine System1 contro1 46 .07 .250 .037 
intervention 42 .07 .261 .040 
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Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Endocrine 
System 
Equal 
variances 
assumed 
1.068 .304 -
.515 
86 .608 -.030 .058 -.146 .086 
Equal 
variances 
not 
assumed 
  
-
.511 
80.441 .611 -.030 .059 -.147 .087 
Endocrine 
System1 
Equal 
variances 
assumed 
.052 .820 -
.114 
86 .909 -.006 .054 -.114 .102 
Equal 
variances 
not 
assumed 
  
-
.114 
84.458 .910 -.006 .055 -.115 .102 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Urogenital System contro1 46 .07 .250 .037 
intervention 42 .10 .297 .046 
Urogenital System1 contro1 46 .02 .147 .022 
intervention 42 .05 .216 .033 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
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Urogenital 
System 
Equal 
variances 
assumed 
1.068 .304 -
.515 
86 .608 -.030 .058 -.146 .086 
Equal 
variances 
not 
assumed 
  
-
.511 
80.441 .611 -.030 .059 -.147 .087 
Urogenital 
System1 
Equal 
variances 
assumed 
1.785 .185 -
.662 
86 .510 -.026 .039 -.104 .052 
Equal 
variances 
not 
assumed 
  
-
.651 
71.609 .517 -.026 .040 -.105 .053 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Musculoskeletal System contro1 46 .00 .000 .000 
intervention 42 .05 .216 .033 
Musculoskeletal System1 contro1 46 .00 .000a .000 
intervention 42 .00 .000a .000 
a. t cannot be computed because the standard deviations of both groups are 0. 
 
 
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Musculoskeletal 
System 
Equal 
variances 
assumed 
9.962 .002 -
1.499 
86 .137 -.048 .032 -.111 .016 
Equal 
variances 
not 
assumed 
  
-
1.432 
41.000 .160 -.048 .033 -.115 .020 
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Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Respiratory System contro1 46 .00 .000 .000 
intervention 42 .07 .261 .040 
Respiratory System1 contro1 46 .00 .000 .000 
intervention 42 .07 .261 .040 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Respiratory 
System 
Equal 
variances 
assumed 
16.234 .000 -
1.860 
86 .066 -.071 .038 -.148 .005 
Equal 
variances 
not 
assumed 
  
-
1.776 
41.000 .083 -.071 .040 -.153 .010 
Respiratory 
System1 
Equal 
variances 
assumed 
16.234 .000 -
1.860 
86 .066 -.071 .038 -.148 .005 
Equal 
variances 
not 
assumed 
  
-
1.776 
41.000 .083 -.071 .040 -.153 .010 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Renal System contro1 46 .07 .250 .037 
intervention 42 .05 .216 .033 
Renal System1 contro1 46 .02 .147 .022 
intervention 42 .00 .000 .000 
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Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Renal 
System 
Equal 
variances 
assumed 
.500 .481 .352 86 .725 .018 .050 -.082 .117 
Equal 
variances 
not 
assumed 
  
.355 85.745 .724 .018 .050 -.081 .116 
Renal 
System1 
Equal 
variances 
assumed 
3.816 .054 .955 86 .342 .022 .023 -.024 .067 
Equal 
variances 
not 
assumed 
  
1.000 45.000 .323 .022 .022 -.022 .066 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Central Nervous System and 
Psychotropic Drugs 
contro1 46 .11 .315 .046 
intervention 42 .10 .297 .046 
Central Nervous System and 
Psychotropic Drugs1 
contro1 46 .09 .285 .042 
intervention 42 .07 .261 .040 
 
 
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
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Central Nervous 
System and 
Psychotropic 
Drugs 
Equal 
variances 
assumed 
.170 .681 .206 86 .837 .013 .065 -.117 .143 
Equal 
variances 
not 
assumed 
  
.206 85.898 .837 .013 .065 -.116 .143 
Central Nervous 
System and 
Psychotropic 
Drugs1 
Equal 
variances 
assumed 
.284 .595 .266 86 .791 .016 .058 -.101 .132 
Equal 
variances 
not 
assumed 
  
.267 85.999 .790 .016 .058 -.100 .131 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Antiplatelet/ Anticoagulant 
Drugs 
contro1 46 .09 .285 .042 
intervention 42 .02 .154 .024 
Antiplatelet/ Anticoagulant 
Drugs1 
contro1 46 .07 .250 .037 
intervention 42 .02 .154 .024 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Antiplatelet/ 
Anticoagulant 
Drugs 
Equal 
variances 
assumed 
7.050 .009 1.275 86 .206 .063 .050 -.035 .162 
Equal 
variances 
not 
assumed 
  
1.308 70.567 .195 .063 .048 -.033 .159 
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Antiplatelet/ 
Anticoagulant 
Drugs1 
Equal 
variances 
assumed 
3.575 .062 .925 86 .357 .041 .045 -.048 .130 
Equal 
variances 
not 
assumed 
  
.945 75.945 .348 .041 .044 -.046 .129 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Cardiovascular contro1 46 .11 .315 .046 
intervention 42 .05 .216 .033 
Cardiovascular1 contro1 46 .11 .315 .046 
intervention 42 .00 .000 .000 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Cardiovascular Equal 
variances 
assumed 
4.676 .033 1.052 86 .296 .061 .058 -.054 .176 
Equal 
variances 
not 
assumed 
  
1.070 79.954 .288 .061 .057 -.053 .175 
Cardiovascular1 Equal 
variances 
assumed 
25.970 .000 2.237 86 .028 .109 .049 .012 .205 
Equal 
variances 
not 
assumed 
  
2.343 45.000 .024 .109 .046 .015 .202 
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Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Fall_meds contro1 46 .0217 .14744 .02174 
intervention 42 .0714 .26066 .04022 
Drugs that predictably 
increase the risk of falls in 
older people1 
contro1 46 .15 .363 .054 
intervention 42 .12 .328 .051 
 
 
Independent Samples Test 
 
Levene's 
Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Fall_meds Equal 
variances 
assumed 
5.213 .025 -
1.113 
86 .269 -.04969 .04465 -.13845 .03907 
Equal 
variances 
not 
assumed 
  
-
1.087 
63.515 .281 -.04969 .04572 -.14104 .04166 
Drugs that 
predictably 
increase the 
risk of falls in 
older people1 
Equal 
variances 
assumed 
.811 .370 .448 86 .656 .033 .074 -.114 .180 
Equal 
variances 
not 
assumed 
  
.450 85.991 .654 .033 .074 -.113 .180 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Indication contro1 46 .13 .341 .050 
intervention 42 .10 .297 .046 
Indication1 contro1 46 .13 .341 .050 
intervention 42 .00 .000 .000 
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Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Indication Equal 
variances 
assumed 
1.074 .303 .514 86 .608 .035 .068 -.101 .171 
Equal 
variances 
not 
assumed 
  
.518 85.833 .606 .035 .068 -.100 .170 
Indication1 Equal 
variances 
assumed 
34.086 .000 2.481 86 .015 .130 .053 .026 .235 
Equal 
variances 
not 
assumed 
  
2.598 45.000 .013 .130 .050 .029 .232 
 
 
Group Statistics 
 group N Mean Std. Deviation Std. Error Mean 
Gastrointestinal contro1 46 .28 .455 .067 
intervention 42 .19 .397 .061 
Gastrointestinal1 contro1 46 .24 .431 .064 
intervention 42 .02 .154 .024 
 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
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Gastrointestinal Equal 
variances 
assumed 
4.193 .044 1.007 86 .317 .092 .091 -.090 .274 
Equal 
variances 
not 
assumed 
  
1.013 85.837 .314 .092 .091 -.089 .273 
Gastrointestinal1 Equal 
variances 
assumed 
60.126 .000 3.060 86 .003 .215 .070 .075 .355 
Equal 
variances 
not 
assumed 
  
3.171 57.268 .002 .215 .068 .079 .351 
 
 
 
 
